Navigation Links
Neovasc Inc. Reports First Quarter 2009 Financial Results
Date:6/1/2009 

    --Company Focuses on Rebuilding Revenue Base While Stabilizing Costs--

    TSX Venture Exchange: NVC

VANCOUVER, June 1 /PRNewswire-FirstCall/ - Vancouver, BC, Canada - Neovasc Inc. (TSXV: NVC), today announced financial results for the three months ended March 31, 2009.

"The first quarter continued to show financial effects from our strategic decision late last year to refocus Neovasc on our most promising growth areas," said Alexei Marko, chief executive officer of Neovasc. "During this transition period we have been laying the groundwork to increase sales from our tissue product line and have continued to advance the development and approval process for our Reducer device for the treatment of refractory angina. Despite the fact that we started the year without a US distributor for our biological tissue products, sales for the quarter were only down slightly compared to last year. We have seen a significant ramp in sales since our agreement with LeMaitre Vascular came into effect and as we continue to grow our business supplying tissue to industry partners developing and manufacturing vascular devices. On the cost side, we have made good progress in reducing our cost structure and continue to focus on wringing unnecessary expense out of the business."

Mr. Marko continued, "Since the close of the quarter, we have had several encouraging developments: We successfully completed a non-brokered private placement of approximately $2.0 million to strengthen our cash position and earlier this month we reported very encouraging preliminary data from the three-year follow-up study of refractory angina patients implanted with our Neovasc Reducer(TM). Refractory angina is a painful and debilitating condition that affects millions of patients and currently lacks effective treatments. The preliminary three-year data indicates that the Reducer was very well tolerated and showed positive signs of efficacy in the majority of pa
'/>"/>

SOURCE Neovasc Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Positive Results for Ophthotechs Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
2. Neovasc Completes $2 Million Non-Brokered Private Placement
3. Neovasc Inc. Reports Year 2008 Financial Results
4. Neovasc to Raise $2 Million in Non-Brokered Private Placement
5. Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
6. Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips
7. Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
8. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
9. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. Unilens Vision Reports Record Third Quarter Revenue, and Royalty Income

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...stography can help differentiate between cancerous...presented today at the annual meeting of the Radio...-frequency ultrasound with elastography has the po...iagnosis," said lead author Eliot L. Siegel, M.D.,...he University of Maryland School of Medicine (UMSM...
(Date:12/1/2009)...lead to early degeneration in the spine, according...of the Radiological Society of North America (RSNA...tion between increased body mass index (BMI) and d...ead author, Judah G. Burns, M.D., fellow in diagno...Montefiore in New York City. , In this retrospe...
(Date:11/30/2009)...y is attempting to dispel the notion that all U.S....ients home pregnant with multiples. While they wa...riority is health and safety. In addition, they a...n a country’s healthcare system. , ...ny patients and doctors in the U.K. worry that cro...
(Date:11/30/2009)... study using functional magnetic resonance imaging...dults who were exposed to lead as children incur p...today at the annual meeting of the Radiological So... found is that no region of the brain is spared fr...im Cecil, Ph.D., imaging scientist at Cincinnati C...
(Date:11/30/2009)... study presented today at the annual meeting of th...ealed that MRI is a highly accurate means of ident...ening and increasingly common condition that is th... after giving birth. ,, "Due to the increase i... scarring on the uterine wall, coupled with women ...
Breaking Medicine News(10 mins):Health News:Special ultrasound accurately identifies skin cancer 2Health News:Overweight children may develop back pain and spinal abnormalities 2Health News:East Coast Fertility Aims to Build Families One Baby at a Time by Applying Single Embryo Transfers to Donor Egg Program 2Health News:East Coast Fertility Aims to Build Families One Baby at a Time by Applying Single Embryo Transfers to Donor Egg Program 3Health News:Childhood Lead Exposure Causes Permanent Brain Damage 2Health News:Childhood Lead Exposure Causes Permanent Brain Damage 3Health News:MRI Helps Detect Life-Threatening Pregnancy Complication 2Health News:MRI Helps Detect Life-Threatening Pregnancy Complication 3
... testing and diagnosis , , TUESDAY, March ...er called Danon disease progresses rapidly and is ...tudy. , The recently recognized disease is a type ...ral course of the disease was unclear. , Researche...
...evelop these infections, , , TUESDAY, Marc... an antibacterial agent to the dressing around the...uce the chances that a potentially deadly infectio...ed States, about 80,000 catheter-related infection...
...16) and HPV type 18 (HPV18) were found in the majo... the 1980s and 1990s, according to a population-ba...f the Journal of the National Cancer Institute. ... other HPV types, which may have implications for ...
...e Activity in Tissue Culture Cells ,Infection wi...n of the telomerase reverse transcriptase (hTERT) ...own in culture. , HCMV has been suspected of caus...y, which promotes cell proliferation and immortali...
...tive health plans that emphasize wellness and allo...yle has produced healthy enrollment growth for MVP...d 743,000 members compared with 700,000 members at...ucts which is a good sign that MVP Health Care is ...
...ical Publisher Ltd. (Schweizerische Arzteverlag AG...ounce an agreement to deploy Aries, Editorial Mana...d by EMH. , , The project will begin with deploy...871 and indexed in Medline, the Swiss Medical Wee...
Other Medicine News:Health News:Danon Disease Can Be Quickly Fatal, Study Finds 2Health News:Drug-Coated Sponges May Limit Catheter Infections 2Health News:Human papillomavirus genotype distribution in New Mexico cervical cancers 2Health News:Also in the March 24 JNCI 2Health News:Also in the March 24 JNCI 3Health News:Also in the March 24 JNCI 4Health News:Also in the March 24 JNCI 5Health News:Also in the March 24 JNCI 6Health News:MVP Health Care Reports Enrollment Growth 2Health News:MVP Health Care Reports Enrollment Growth 3Health News:EMH Swiss Medical Publisher Ltd. Selects Editorial Manager for Online Peer Review 2
(Date:12/1/2009)...ICAGO, Dec. 1 ,, Ov... Abnormalities ,, A study from The Children,s ... children who are overweight may be causing damage...f the spines of 188 adolescents between the ages o...maged at the hospital over a four-year period. The...
(Date:12/1/2009)... , NEW YORK, Dec. 1 The g...ing market dynamics for an industry experiencing s... reforms are likely to drive up the effective tax...industry, according to a report released today by ...ng times ahead - Which path will you take? The in...
(Date:12/1/2009)... , BOSTON, Dec. 1 An...sdaq: PRXL ), a leading global biopharmaceutical ... innovative approaches to drug development in Asia...ic Conference, being held December 1-3, 2009 at th...a sponsor of the conference, which is focused on m...
Breaking Medicine Technology:Tuesday, Dec. 1: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago 2Tuesday, Dec. 1: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago 3Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers 2Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers 3Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers 4Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers 5PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 2PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 3PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 4Long Term Lead Exposure Linked to Heart Deaths 56480 1Long Term Lead Exposure Linked to Heart Deaths 56480 2Caliper Life Sciences to Present at UBS Global Life Sciences Conference 56476 1PA Helping Life Science Companies Secure Venture Capital Needed to Expand Gov Rendell Says 13911 1PA Helping Life Science Companies Secure Venture Capital Needed to Expand Gov Rendell Says 13911 2
...Urological Association Annual Meeting -- , , SEAT...on Corporation (Nasdaq: DNDN ) today presented p...263, Dendreon,s orally bioavailable small molecule...nel protein), to treat benign prostatic hyperplasi...e BPH alone and in combination with finasteride, a...
...il 28 Debiopharm Group,(Debiopharm), a global bio...,on serious medical conditions, particularly in th... IIa study with Debio 025, a selective,cyclophilin...CV) effect.,Revealed at the 44th Annual Meeting of...er, in Copenhagen, these findings showed potent an...
Other Medicine Technology:Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 2Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 3Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 4Clinical Update - Debio 025 in Hepatitis C 2Clinical Update - Debio 025 in Hepatitis C 3
6075-504 Custom Nebulizer Kit
...s, ,Westmed designs, manufacturers and markets le...espiratory professionals. Our mission is to design...an's ability to deliver quality medical care while...r web site is designed with our customers in mind....
...s, ,Westmed designs, manufacturers and markets le...espiratory professionals. Our mission is to design...an's ability to deliver quality medical care while...r web site is designed with our customers in mind....
...s, ,Westmed designs, manufacturers and markets le...espiratory professionals. Our mission is to design...an's ability to deliver quality medical care while...r web site is designed with our customers in mind....
Medicine Products: